Dr. de Keizer is assistant professor at the University Medical Center in Utrecht. He did his training at Utrecht University and Harvard Medical School and was a visiting scholar at the Buck Institute. After his training he started his career as a group leader at the Erasmus University Medical Center in Rotterdam before moving to his current position at the University Medical Center in Utrecht. His research focuses on cell senescence and the development of drugs, senolytics, that can selectively kill senescent cells. In 2017 Dr. de Keizer published the results from the third generation FOXO-DRI senolytic peptide in the journal Cell showing that it selectively eliminated senescent cells and improved the health of old mice. He is the co-founder of Cleara Biotech BV that is working on bringing these therapies to the market.